Genomic & Molecular Pathology (GMP)

Overview

Division Chief: Eric J. Duncavage, MD
Associate Division Chief: Molly Schroeder, PhD, FACMG

The Division of Genomic and Molecular Pathology (GMP) at WashU Medicine is a national leader in clinical genomic testing, building on the university’s historic contributions to the Human Genome Project and its landmark achievement in sequencing the first cancer genome in 2008. In collaboration with the CAP/CLIA-accredited laboratory at the McDonnell Genome Institute, the GMP Division has developed and launched several pioneering clinical assays, including:

• GPS v1.0 (2011): the first NGS-based solid tumor cancer panel
• SOMA (2013): the first NGS-based panel for somatic overgrowth syndromes
• MyeloSeq MRD (2019): the first NGS-based assay for minimal residual disease in myeloid neoplasms
• ChromoSeq (2021): the first clinical whole genome sequencing-based assay for myeloid malignancies

Today, the GMP Division offers a comprehensive menu of genomic tests for inherited disorders, oncology, and other genetic diseases. These assays support precision medicine at WashU Medicine by guiding therapeutic decisions and improving patient outcomes.

Our faculty collaborate extensively across the School of Medicine, as well as with pharmaceutical partners and research consortia, to advance patient care, support clinical trials, and drive innovation in genomic science.